Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ITGA1 | P56199 | 3/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140911 | 1.00 | MAPK1 (0.41) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4142783 | 0.94 | MAPK1 (0.42) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4142787 | 0.94 | MAPK1 (0.42) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4143372 | 0.93 | MAPK1 (0.41) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4143367 | 0.93 | MAPK1 (0.41) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4136390 | 0.92 | MAPK1 (0.40) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL13872707 | 0.92 | MAPK1 (0.40) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4140598 | 0.92 | MAPK1 (0.40) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4127419 | 0.91 | MAPK1 (0.39) | MAPK1TRPV4GAAITGA1PSMB5 | |
| SCHEMBL4127414 | 0.91 | MAPK1 (0.39) | MAPK1TRPV4GAAITGA1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | MAPK1 1486/4885TRPV4 1/4885GAA 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.